26 Jan 2010 16:15
| For immediate release | 26 January 2010 |
Futura Medical plc
("Futura" or "the Company")
Correction of Director's Dealings
Futura Medical plc (AIM: FUM) announces a correction to its director's dealing announcement of 17 December 2009 (the "Original Announcement").
In the Original Announcement James Barder's aggregate beneficial and non-beneficial holdings was described as "unchanged at 720,212 ordinary shares". This number should have been stated as "unchanged at 845,212 ordinary shares". This is a correction and does not reflect any change to Mr Barder's actual holding.
For any further information please contact:
| Futura Medical plc | |
| James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
| mail to: james.barder@futuramedical.com | www.futuramedical.com |
| Nomura Code Securities Limited | |
| Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
| For media enquiries please contact: | |
| Buchanan Communications | |
| Mark Court / Stasa Filiplic / Jennie Spivey | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)